On January 24, 2023 -ENB Therapeutics, Inc., a biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, reported that the company has been selected for oral presentations at the 2023 BIO CEO and IO 360o conferences (Press release, ENB Therapeutics, JAN 24, 2023, View Source [SID1234626519]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BIO CEO conference is taking place from February 6-9, 2023 in New York City at the New York Marriott Marquis. In its 25th year, BIO CEO is one of the largest investor conferences in the life science industry. ENB will be available for in person and virtual partnering meetings To learn more go to: View Source
Presenter: Sumayah Jamal, MD-PhD
Date: Monday, February 6, 2023
Location and Time: 2:00 pm in Music Box room
IO 360 conference is taking place in New York City at the New York Marriott at the Brooklyn Bridge from February 7-10. It is a premier meeting focused on the latest advances in immuno-oncology. ENB will be available for in person and virtual partnering meetings. To learn more go to: View Source
Presenter: Sumayah Jamal, MD-PhD
Date: Thursday, February 9, 2023
Location and Time: 11:20-12:15 IO 360 Biotech Showcase
About ENB-003
ENB-003 is a selective endothelin B receptor (ETBR) inhibitor that, in preclinical studies, enhanced the efficacy of immunotherapies such as anti-PD-1, anti-CTLA-4 and CAR T across multiple cancer types in preclinical studies. In an ongoing multi-center Phase 1/2 clinical trial, early efficacy signals suggest that ENB-003 overcomes resistance to the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in heavily pre-treated drug resistant cancer patients. The Phase 2 portion of the ENB-003 + pembrolizumab combination study is expected to start in the first quarter of 2023. The trial will enroll melanoma patients with innate resistance to anti-PD-1 based immunotherapies, platinum refractory and platinum resistant ovarian cancer patients, as well pancreatic cancer patients that have failed standard of care.